Jenburkt Pharma shares admitted to NSE 'Permitted to Trade' category
- Shares admitted to NSE 'Permitted to Trade' category effective August 17, 2026
- Company confirms it did not apply for NSE listing; primary listing remains on BSE
- Admission based on NSE Circular No. NSE/CML/75748 dated August 14, 2026
*this image is generated using AI for illustrative purposes only.
Jenburkt Pharmaceuticals Limited equity shares have been admitted to the National Stock Exchange of India Limited (NSE) under the “Permitted to Trade” category. This admission is effective from August 17, 2026, following a circular issued by the exchange.
The company confirmed that it did not apply for this listing. The shares remain primarily listed on the BSE Limited. The inclusion on NSE is automatic under the specified category, allowing trading without a formal application from the issuer.
Regulatory context and disclosure
The intimation was filed pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Jenburkt Pharmaceuticals stated that it became aware of the development through NSE Circular No. NSE/CML/75748 dated August 14, 2026.
The company noted that no separate communication or intimation regarding this admission was received directly from the NSE prior to the public circular. The disclosure was made subsequently for the information of shareholders and stakeholders.
Key details of the admission
| Detail | Information |
|---|---|
| Effective Date | August 17, 2026 |
| Category | Permitted to Trade |
| Exchange | National Stock Exchange of India Limited (NSE) |
| Primary Listing | BSE Limited |
| Application Status | No application made by the company |
This move enhances liquidity options for investors by making the shares accessible on the NSE platform, although the primary regulatory obligations and listing status remain anchored with BSE.
Historical Stock Returns for Jenburkt Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -2.29% | -4.65% | -6.93% | -8.41% | -8.41% | -8.41% |
How might the automatic NSE listing impact Jenburkt Pharmaceuticals' trading volume and bid-ask spreads compared to its current BSE activity?
Will the dual-exchange presence influence the company's future capital raising strategies or attract a broader institutional investor base?
Could this precedent of automatic admission encourage other BSE-only listed companies to reassess their primary exchange preferences?
20
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
